Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. - Wikidata - wikimedia - TriplyDB

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.

http://www.wikidata.org/entity/Q34866510

about

EZH2 in Bladder Cancer, a Promising Therapeutic Target Bladder cancer in the elderly patient: challenges and solutions A place for precision medicine in bladder cancer: targeting the FGFRs.Computational approaches to study the effects of small genomic variations.Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs.The NF1 somatic mutational landscape in sporadic human cancers.Identification of ALK gene alterations in urothelial carcinoma.A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary.Long noncoding RNA GHET1 promotes the development of bladder cancer Canonical Notch signalling is inactive in urothelial carcinoma.Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin Modelling bladder cancer in mice: opportunities and challenges.Novel molecular targets for urothelial carcinoma DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors.Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma HER2 as a target in invasive urothelial carcinoma.Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing: Implications for Surgical Management Mutations in chromatin machinery and pediatric high-grade glioma An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion.Combined Genetic Biomarkers Confer Susceptibility to Risk of Urothelial Bladder Carcinoma in a Saudi Population.Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination Tp53 and its potential therapeutic role as a target in bladder cancer.Driver mutations of cancer epigenomes.Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma.Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma.Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer.Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.Expression of MDM2 mRNA, MDM2, P53 and P16 Proteins in Urothelial Lesions in the View of the WHO 4th Edition Guidelines as a Molecular Insight towards Personalized Medicine.Quantitative analysis of the association between sulfotransferase isoform 1A1 polymorphism and risk of urothelial carcinoma.In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer.

P2860

Q28082054-26B19AD8-DBAA-41DC-B723-689CBC519DA6 Q28082782-8AF3FADE-1D20-48D0-B5E3-31F9280DD32F Q30249143-7A64CBDD-79D0-4B07-A315-3B466085AB08 Q30378925-9EE075CF-24D5-42A4-B511-3988C652E5DA Q33593041-9F952D21-21D6-4BE3-8915-B4120D8FF25D Q33823452-F3262891-A045-4B97-9716-81D7FA8DBF53 Q33989002-8201EEFE-46E3-4CA7-8BAD-BC61E4842DFE Q34081624-782C4630-893A-4138-8E69-343AC266971C Q34181172-63B9ADAB-BA82-4280-807A-E636B568B9E6 Q34501968-B8F6E13E-D32B-44E3-B928-7ADB9DDD6EC2 Q34565523-74D926DF-C715-461B-BF7B-3AABCD9048A1 Q34959996-2DE751E4-712D-4058-9EA7-19E6198BB2F9 Q35285703-D4168701-06B9-44D8-9F8F-A664C01A7064 Q35527068-14890476-7856-4A0B-AEAF-5E09010DE622 Q35606694-29B0E61F-A8AB-4DB7-A0D3-6ADA238EA5B8 Q35651546-3928AC7A-58E9-44E8-9398-5021B4EC5FE4 Q35731224-1D67D775-8090-4EB2-AF5F-4B818B9F4E87 Q35755382-BC01F16E-57C8-4F60-8B46-92183EA0074A Q35864528-3ACCE645-98A9-45BF-B93A-0DC1D692D0E5 Q36215971-E58ADD3F-EF10-437F-89B4-C2414A472DAA Q36326886-A2EE2D9D-422C-4B37-858E-6C6758282310 Q36716785-988E613D-74A3-449A-A7E2-27A46D691C87 Q36779225-AE5730DA-C5B7-4C07-988C-D3D0099EAE1C Q36900873-954EE10C-7DF0-414F-8142-1D3CFD9AC028 Q36983860-18554BED-1112-4AFA-BF34-0B5811570495 Q37012561-F8797D83-2589-4FC2-8C7D-520AC84B92CC Q37446067-76A3A2B9-3D78-4F20-AD3D-2102BC64C528 Q37588340-5EE96E22-4F1C-4420-AE05-CF0BD8C09FCF Q37699997-CCC0519D-7F97-4B01-9B31-D297CE42CA15 Q38225521-E3710CA4-408C-479E-81CE-88B3076AB975 Q38436074-E265466A-D30F-49DF-8264-3D6B4FCD7006 Q38639828-5F4770F8-9847-4A61-9004-FE3353A70E08 Q38714341-D2DB7F1B-D3EA-4184-A695-77ACB578A295 Q38715315-E5528DBB-6FCA-46ED-9404-259143EE84B1 Q38810603-DE479627-7B6D-49FB-BD4F-E7BEE44F0AD9 Q38906194-3CAE0005-8DE4-49CA-84A4-06782098FE3D Q40275671-4E8D7952-96A8-42C4-816E-9E4B8E703BF8 Q41465239-87FF1336-ECB4-4A5A-89FB-8F54FB3CAEEC Q42023659-F83F7232-D4AD-4281-BEC9-9C6A45AC26A8 Q42550010-F6B7F245-5D78-41B9-A457-E0B7843FDFB9

P2860

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.

http://www.wikidata.org/entity/Q34866510

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Advanced urothelial carcinoma: ...... ations and targets of therapy.

@ast

Advanced urothelial carcinoma: ...... ations and targets of therapy.

@en

Advanced urothelial carcinoma: ...... ations and targets of therapy.

@nl

type

label

Advanced urothelial carcinoma: ...... ations and targets of therapy.

@ast

Advanced urothelial carcinoma: ...... ations and targets of therapy.

@en

Advanced urothelial carcinoma: ...... ations and targets of therapy.

@nl

prefLabel

Advanced urothelial carcinoma: ...... ations and targets of therapy.

@ast

Advanced urothelial carcinoma: ...... ations and targets of therapy.

@en

Advanced urothelial carcinoma: ...... ations and targets of therapy.

@nl

P1433

Q34866510-490C8643-6D59-4E84-B882-6DE23D635998

P1476

Q34866510-1ADA6B35-5077-4AB5-959F-D15135C02D80

P2093

Q34866510-014507ED-98C3-4385-919C-DC3A102D17F3

Q34866510-052EBC18-4E22-466C-9AF7-870922F17BFF

Q34866510-1671CED1-3473-4E6C-B3E6-8113E647153A

Q34866510-16AE0758-A605-4BDA-A1AB-B97C650B55F7

Q34866510-184B9AE7-6167-445B-A92E-40E976278D46

Q34866510-187AF5E7-B5CF-4A78-A112-14ADBB84955D

Q34866510-2702B1B3-B42A-42A4-BD14-375827C5D3C7

Q34866510-624834F8-9021-4444-ADAE-F630C6D629D0

Q34866510-66FF7429-7868-4D71-8EDC-3143F6528F3E

Q34866510-696564D4-8350-4ED6-9CAB-7A754539DC04

P2860

Q34866510-04894060-5445-447D-96BC-95A6B16BD750

Q34866510-06043F30-D3B8-4CC4-B1BA-31E39E76D59D

Q34866510-0B5BF359-A23E-4DDB-B90C-0FB9CEFC0F73

Q34866510-0B5D1899-BA6E-457A-A812-99439FCCCB91

Q34866510-0FB3A359-2D4C-44C9-9260-43450303D81E

Q34866510-12CEA761-A551-4256-93DB-D4936CA40368

Q34866510-196FAEE7-D970-426D-BDA3-FB661F83F444

Q34866510-1B3F61C5-4C23-45F4-B364-A2B05B38C278

Q34866510-1CC911B5-0406-4359-A092-576E32A6E4C9

Q34866510-1DA21E2A-334B-4FB8-9CA4-37E755AFBE37

P2888

Q34866510-5B798B83-E51C-4CB0-9F94-9D74BA480133

P304

Q34866510-286120BF-2A10-454C-A54C-A5580E548231

P31

Q34866510-F72107FD-D278-40D7-8A08-023FD2349D97

P356

Q34866510-43DE98CC-3ECF-43DF-AB4A-812C8057D028

P433

Q34866510-F3AC95EF-D37D-4479-B8B0-8AFF9B8673E3

P478

Q34866510-C564D3FD-79F8-4F4C-82C8-6237BDB7805E

P577

Q34866510-5F90D24D-319E-4F09-80F1-53D191A0EF70

P6179

Q34866510-28FC78BF-8A2B-41DF-B303-E946484DB8D2

P698

Q34866510-BDAECB3D-3E15-4AED-A088-64B0B9AA3F47

P356

MODPATHOL.2013.135

P1433

Modern Pathology

P1476

Advanced urothelial carcinoma: ...... ations and targets of therapy.

@en

P2093

Christine E Sheehan

http://www.w3.org/2001/XMLSchema#string

Doron Lipson

http://www.w3.org/2001/XMLSchema#string

Gary Palmer

http://www.w3.org/2001/XMLSchema#string

Geoff A Otto

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Ross

http://www.w3.org/2001/XMLSchema#string

Jie He

http://www.w3.org/2001/XMLSchema#string

John A Curran

http://www.w3.org/2001/XMLSchema#string

Kai Wang

http://www.w3.org/2001/XMLSchema#string

Kristen Mahoney

http://www.w3.org/2001/XMLSchema#string

Lazlo Garcia

http://www.w3.org/2001/XMLSchema#string

P2860

Genome sequencing identifies a basis for everolimus sensitivity

Cancer statistics, 2012

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

The Sequence Alignment/Map format and SAMtools

Raf kinases in cancer-roles and therapeutic opportunities

Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing

Fibroblast growth factor signalling: from development to cancer

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.

Transforming fusions of FGFR and TACC genes in human glioblastoma.

P2888

modpathol.2013.135

P304

271-280

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.2013.135

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1025381432

http://www.w3.org/2001/XMLSchema#string

P698

23887298

http://www.w3.org/2001/XMLSchema#string